The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. Key therapies expected to fuel growth are the recently approved CAR T-cell therapies Yescarta (Gilead / Kite) and Kymriah (Novartis) as well as novel targeted agents. In addition, combinations incorporating the BTK inhibitors Imbruvica (Janssen) and Calquence (Acerta / AstraZeneca), the Bcl-2 inhibitor Venclexta / Venclyxto (AbbVie / Roche), and anti-CD20 monoclonal antibodies will enter the market, which will result in a shift away from conventional immunochemotherapy regimens. Offsetting this market growth will be the biosimilar erosion expected for rituximab (a key 2018 patient- and market-share leader in the NHL space) and the generic erosion of Celgene’s Revlimid. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in underserved patient segments.

Questions Answered:

  • Which emerging therapies are the most promising in NHL, and what patient populations will they target? What will be their impact on the NHL market?
  • How will market share for rituximab change over the ten-year forecast period as a result of biosimilar entry? Will Roche / Genentech’s Gazyva / Gazyvaro and Rituxan Hycela / MabThera SC be able to minimize the impact of biosimilar erosion of branded rituximab? 
  • The NHL therapy market will experience robust growth through 2028. What factors are driving growth in the NHL market? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DLBCL, and mantle cell lymphoma (MCL).

Population segments in market forecast: First line, second line, third line and fourth line for FL, CLL/SLL, DLBCL, and MCL.

Emerging therapies: Phase I/II: 29 drugs; Phase III / PR: 9 drugs.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Non-Hodgkin's Lymphoma - Key Findings
    • Key Updates
      • May 2020
      • March 2020
      • November 2019
      • August 2019
      • May 2019
      • February 2019
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for NHL?
        • What Factors Are Constraining the Market for NHL?
      • Segment-Specific Trends
        • First-Line CLL / SLL
        • Relapsed/Refractory CLL / SLL
        • First-Line DLBCL
        • Relapsed/Refractory DLBCL
        • First-Line FL
        • Relapsed/Refractory FL
        • First-Line MCL
        • Relapsed/Refractory MCL
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
      • Staging and Classification
        • Staging of NHL
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • De Novo DLBCL Incident Cases by Molecular Subtype
        • Transformed Incident Cases from FL to DLBCL
        • Transformed Incident Cases from CLL to DLBCL
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Monoclonal Antibodies
        • Apoptosis-Inducing Agents
        • Immunomodulatory Agents
        • Proteasome Inhibitors
        • mTOR Inhibitors
        • BTK Inhibitors
        • PI3K Inhibitors
        • Cytotoxic agents
        • CAR T-Cell Therapies
        • Antibody-Drug Conjugates
        • Immune Checkpoint Inhibitors
      • Medical Practice
        • Drug-Treatable Population
        • Country-Specific Treatment
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in NHL
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for NHL
        • Kinase Inhibitors
        • Monoclonal Antibodies/Bispecific Antibodies
        • Antibody-drug conjugates
        • CAR T-Cell Therapies
        • Immune Checkpoint Inhibitors
        • Selective Inhibitors of Nuclear Export
        • EZH2 Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for NHL
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Non-Hodgkin's Lymphoma Bibliography

Author(s): Sorcha Cassidy M.Res., Ph.D; Stephanie Niquita; Priyanka Mehra, B.Tech

Sorcha Cassidy , is an Associate Director in the Oncology team at Decision Resources ; Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an and in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.

Stephanie Niquita works as an associate epidemiologist at Decision Resources Group. Stephanie holds a masters in public health specializing in epidemiology from TISS, Mumbai and a medical degree from Hubei University of Chinese Medicine, People’s Republic of China. She has been trained as a community physician and has also supervised and coordinated various governmental and non-governmental public health projects.

Priyanka Mehra is a Business Insights Analyst in the oncology team at Decision Resources Group. She has 5+ years of work experience in pharmaceutical research and analytics, involving management and execution of various strategic analysis projects across multiple oncology indications, secondary and primary research and competitive intelligence. Previously, she worked as an Associate Consultant with Prescient Healthcare Group where she handled Biosimilars projects for global pharmaceutical clients and designed brand and commercial strategy solutions on a variety of therapy areas, including oncology, immunology and inflammatory diseases. Prior to Prescient, she worked as a Senior Analyst with Smart Analyst where she worked on indication prioritization and clinical landscapes for major oncology indications such as NHL, NSCLC and CRC. She has also worked as a Senior Analyst with BioXcel Corporation where she was involved with projects on clinical trials and pipeline analysis, performance benchmarking, scouting and product profiling.

Related Reports

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2019

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/R

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Epidemiology | Mature Markets Non-Hodgkin's Lymphoma

DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) comprises epidemiological estimat...

View Details